Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

(2016) Matt Stevenson et al.   HEALTH TECHNOLOGY ASSESSMENT

Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis

(2016) Saeed Ahmadiani et al.   RHEUMATOLOGY INTERNATIONAL

Infecções graves em pacientes com artrite reumatoide em uso de anakinra, rituximab ou abatacept: revisão sistemática de estudos observacionais

(2016) Vanderlea Poeys Cabral et al.   Revista Brasileira De Reumatologia

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

(2015) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain — Interleukin-8 in fibromyalgia and interleukin-1 β in rheumatoid arthritis

(2015) Eva Kosek et al.   JOURNAL OF NEUROIMMUNOLOGY

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   Arthritis & Rheumatology

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

(2014) Cécile Gaujoux-Viala et al.   ANNALS OF THE RHEUMATIC DISEASES

The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study

(2014) Marita Cross et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis

(2014) Jeroen P Jansen et al.   Health and Quality of Life Outcomes

IL-1 Trap rilonacept in refractory adult onset Still's disease

(2012) Olga Petryna et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-Term Efficacy and Safety Profile of Rilonacept in the Treatment of Cryopryin-Associated Periodic Syndromes: Results of a 72-Week Open-Label Extension Study

(2012) Hal M. Hoffman et al.   CLINICAL THERAPEUTICS

Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis

(2012) Kalle J. Aaltonen et al.   PLoS One

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

(2011) Rieke Alten et al.   BMC MUSCULOSKELETAL DISORDERS

Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis

(2011) Jun Bao et al.   CLINICAL RHEUMATOLOGY

GRADE guidelines: 3. Rating the quality of evidence

(2011) Howard Balshem et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

(2011) J. B. Galloway et al.   RHEUMATOLOGY

Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors

(2011) Armen Yuri Gasparyan et al.   RHEUMATOLOGY INTERNATIONAL

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Anakinra for Rheumatoid Arthritis: A Systematic Review

(2009) M. MERTENS et al.   JOURNAL OF RHEUMATOLOGY

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

(2008) C Salliot et al.   ANNALS OF THE RHEUMATIC DISEASES